Corpus overview


MeSH Disease

Human Phenotype



There are no seroprevalence terms in the subcorpus

    displaying 1 - 2 records in total 2
    records per page

    COVID-19 in rheumatic diseases MESHD: A random cross-sectional telephonic survey

    Authors: Uma Kumar; Rudra Prosad Goswami; Danveer Bhadu; Maumita Kanjilal; Sandeep Nagar; Pallavi Vij; Dheeraj Mittal; Lakshman Meena; Debaditya Roy

    doi:10.1101/2020.08.09.20170985 Date: 2020-08-13 Source: medRxiv

    Objective. To describe the incidence, clinical course, and predictive factors of coronavirus 2019 (COVID-19) infection MESHD in a cohort of rheumatological patients residing in New Delhi (National Capital Region), India. Methods. We performed a cross-sectional, random telephonic survey from 20th April to 20th July 2020 on patients with rheumatic diseases MESHD. Patients were interviewed with a predesigned questionnaire. The incidence of COVID-19 in the general population was obtained from open access government data repository. Report of reverse transcriptase polymerase chain reaction report was taken as confirmatory of COVID-19 infection MESHD. Results. Among the 900 contacted patients 840 responded (713 with rheumatoid arthritis HP rheumatoid arthritis MESHD ( RA MESHD), 100 with systemic lupus erythematosus HP systemic lupus erythematosus MESHD ( SLE MESHD), 20 with spondylarthritis MESHD ( SpA MESHD) and 7 with others; mean age TRANS 45 years, mean duration 11.3 years; 86% female TRANS). Among them 29 reported flu-like symptoms and four RA MESHD patients had confirmed COVID-19 infection MESHD. All of them were hospitalized with uneventful recovery. Rheumatological drugs were discontinued during the infectious episode. Disease modifying agents and biologics were equally received by those with or without COVID-19. The incidence of COVID-19 was similar to general Delhi population (0.476% vs 0.519% respectively, p=0.86). Two patients had relapse of rheumatic disease MESHD after recovery. After recovery from COVID-19 or Flu-like illness, eight patients (27.6%, 95% confidence interval 14.7-45.7) reported disease flare. Conclusion. Patients with rheumatic diseases MESHD in India have similar incidence of COVID-19 infection MESHD compared to the community. Relapse of underlying rheumatic disease MESHD after recovery is not uncommon and continuation of glucocorticoid through the infection should be considered.

    Determinants of cardiac adverse events of chloroquine and hydroxychloroquine in 20 years of drug safety surveillance reports

    Authors: Isaac V Cohen; Tigran Makunts; Talar Moumedjian; Masara Issa; Ruben Abagyan

    doi:10.1101/2020.05.19.20107227 Date: 2020-05-26 Source: medRxiv

    Chloroquine (CQ) and hydroxychloroquine (HCQ) are on the World Health Organization's List of Essential Medications for treating non-resistant malaria MESHD, rheumatoid arthritis HP rheumatoid arthritis MESHD ( RA MESHD) and systemic lupus erythematosus HP systemic lupus erythematosus MESHD ( SLE MESHD). In addition, both drugs are currently used off-label in hospitals worldwide and in numerous clinical trials for the treatment of SARS-CoV-2 infection MESHD. However, CQ and HCQ use has been associated with cardiac side effects, which is of concern due to the higher risk of COVID-19 complications in patients with heart related disorders, and increased mortality associated with COVID-19 cardiac complications. In this study we analyzed over thirteen million adverse event reports form the United States Food and Drug Administration Adverse Event Reporting System to confirm and quantify the association of cardiac side effects of CQ and HCQ. Additionally, we identified several confounding factors, including male TRANS sex, NSAID coadministration, advanced age TRANS, and prior diagnoses contributing to the risk of drug related cardiotoxicity MESHD. These findings may help guide therapeutic decision making and ethical trial design for COVID-19 treatment.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.